Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
58 Leser
Artikel bewerten:
(0)

"The 4th WHO Informal Consultation for Improving Influenza Vaccine Virus Selection" - A Global Meeting Co-organized by WHO and PolyU

HONG KONG, November 17, 2015 /PRNewswire/ --

With the mission to enhance food safety and reduce risks through innovative ways, the Food Safety and Technology Research Centre (FSTRC) at the Department of Applied Biology and Chemical Technology (ABCT) of The Hong Kong Polytechnic University (PolyU) initiated research programmes to address "food safety at source". These include research on vaccines for the control of infections in farmed animals with the aim to reduce human infections by animal viruses. In this connection, ABCT and the Global Influenza Programme (GIP) of the World Health Organization (WHO) are co-organizing a meeting entitled "The 4th WHO Informal Consultation for Improving Influenza Vaccine Virus Selection" to be held in Hong Kong from 18th to 20th of November, 2015. The first three meetings were previously held in Geneva. The main objective of the meeting is anticipate more accurately the flu virus strains which will be circulating so that flu vaccines produced can better target the prevalent virus strain at the time of vaccination. The informal consultation will bring together approximately 120 local and international influenza experts to discuss methods to enhance global surveillance of circulating and emerging influenza viruses. The experts will also explore new technologies to study such viruses to inform the vaccine virus selection process. Recommendations for vaccine viruses for influenza vaccine production are made in February and September each year after careful comparison of recent circulating viruses globally.

Following the WHO meeting, ABCT also collaborates with the Global Initiative on Sharing All Influenza Data(GISAID) and the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) with support from WHO to organise a training workshop on "Genetic Analyses of Influenza Viruses" at the PolyU campus on 21to 22 of November, 2015. The training workshop will enable laboratories to contribute to and benefit from the extensive genetic and related data on influenza viruses, in relation to understanding the epidemiology, the evolution of the viruses, the emergence as well as spread of novel genetic and antigenic variants of influenza. Participants will be instructed on advanced analytical tools for the identification and interpretation of mutations underlying the evolution and antigenic variation of human and animal influenza viruses. Participating institutions will also share insights into human and animal influenza surveillance and research.

Co-organizing the current meeting with WHO and the associated workshop with GISAID allow PolyU researchers to share practices and insights of our animal influenza vaccine programme with key leaders in the field, and provide inspirations for the development of new method of vaccine administration and delivery.

Outbreaks of infections in food animal not only create substantial economic loss, but also create stress on our food supply as well as the possibilities of spreading such infections to human. Animal vaccine is the best approach to prevent such diseases on economic, environmental and ethical grounds, reducing the use of antibiotics in the farming of land animals and aquaculture industries. Europe, the United States and other developed countries have been the main force of animal vaccine markets in the world, while the fast-growing market of China and other emerging countries revealed an increasing demand on animal vaccines targeting local farming animals and aquaculture. Making use of this exchange opportunity, FSTRC will combine its research strengths in nutrition and food microbiology, award-winning technology in nanomaterial development and encapsulation with animal vaccine research. This will result in more innovative ways to improve administration of vaccines, such as submersion and oral vaccination, as well as improved efficacy and effectiveness through better vaccine delivery.

Press contacts
Dr Kevin Wing-hin KWOK
Research Assistant Professor, Department of Applied Biology and Chemical Technology
Telephone: +(852)-3400-8687
E-mail: kwh.kwok@polyu.edu.hk

Dr Amber Jiachi CHIOU
Research Assistant Professor, Department of Applied Biology and Chemical Technology
Telephone: +(852)-3400-8664
E-mail: jiachi.amber.chiou@polyu.edu.hk

Prof. John Siu-lun TAM
Visiting Professor, Department of Applied Biology and Chemical Technology
Telephone: +(852)-3400-8726
E-mail: john.sl.tam@polyu.edu.hk

© 2015 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.